MicroRNA-561-3p indirectly regulates the PD-L1 expression by targeting ZEB1, HIF1A, and MYC genes in breast cancer DOI Creative Commons

Atena Yousefi,

Fattah Sotoodehnejadnematalahi, Nahid Nafissi

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: March 10, 2024

Abstract Globally, breast cancer is the second most common cause of cancer-related deaths among women. In cancer, microRNAs (miRNAs) are essential for both initiation and development tumors. It has been suggested that tumor suppressor microRNA-561-3p (miR-561-3p) crucial in arresting growth cells. Further research necessary to fully understand role molecular mechanism miR-561 human BC. The aim this study was investigate inhibitory effect miR-561-3p on ZEB1 , HIF1A MYC expression as oncogenes have impact PD-L1 overexpression cellular processes such proliferation, apoptosis, cell cycle (BC) lines. genes were measured BC clinical samples lines via qRT-PCR. luciferase assay, MTT, Annexin-PI staining, experiments used assess candidate gene expression, progression. Flow cytometry effects suppression line. assay showed miRNA-561-3p targets 3′-UTRs significantly. tissues, qRT-PCR results demonstrated downregulated up-regulated. shown decreased induced apoptosis arrest through downregulation oncogenes. Furthermore, inhibition by reduced at mRNA protein levels. Our investigated cells first time. findings may help clarify regulation point miR a potential biomarker novel therapeutic target immunotherapy.

Language: Английский

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment DOI Creative Commons

Katie Hudson,

Neil A. Cross, Nicola Jordan

et al.

Frontiers in Immunology, Journal Year: 2020, Volume and Issue: 11

Published: Oct. 21, 2020

Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its receptor PD-1 expressed by T cells and other regulate responses; ultimately preventing exacerbated activation autoimmunity. Many tumours exploit this mechanism overexpressing PD-L1 which often correlates with poor prognosis. Some have also recently been shown express PD-1. On tumours, binding on promotes evasion tumour progression, primarily inhibition of cytotoxic lymphocyte effector function. PD-1/PD-L1-targeted therapy has revolutionised the cancer landscape become first-line treatment for some cancers, due their ability promote durable anti-tumour responses in select patients advanced cancers. Despite clinical success, be unresponsive, hyperprogressive or develop resistance therapy. The exact mechanisms are still unclear. This review will discuss current status therapy, new emerging tumour-intrinisic roles how they may contribute progression immunotherapy as different oncology models.

Language: Английский

Citations

160
Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway DOI Creative Commons
Muhammad Tufail,

Jia-Ju Hu,

Jie Liang

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Jan. 3, 2024

Abstract Breast cancer (BC) is a multifaceted disease characterized by distinct molecular subtypes and varying responses to treatment. In BC, the phosphatidylinositol 3-kinase (PI3K) pathway has emerged as crucial contributor development, advancement, resistance This review article explores implications of PI3K in predictive, preventive, personalized medicine for BC. It emphasizes identification predictive biomarkers, such PIK3CA mutations, utility profiling guiding treatment decisions. The also discusses potential targeting preventive strategies customization therapy based on tumor stage, subtypes, genetic alterations. Overcoming inhibitors exploring combination therapies are addressed important considerations. While this field holds promise improving patient outcomes, further research clinical trials needed validate these approaches translate them into practice. Graphical

Language: Английский

Citations

25
Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: Role of microRNAs and upstream mediators DOI
Milad Ashrafizadeh, Ali Zarrabi, Kiavash Hushmandi

et al.

Cellular Signalling, Journal Year: 2020, Volume and Issue: 78, P. 109871 - 109871

Published: Dec. 4, 2020

Language: Английский

Citations

122
Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery DOI Creative Commons
Sepideh Mirzaei, Ali Zarrabi,

Farid Hashemi

et al.

Antioxidants, Journal Year: 2021, Volume and Issue: 10(3), P. 349 - 349

Published: Feb. 26, 2021

Doxorubicin (DOX) is extensively applied in cancer therapy due to its efficacy suppressing progression and inducing apoptosis. After discovery, this chemotherapeutic agent has been frequently used for therapy, leading chemoresistance. Due dose-dependent toxicity, high concentrations of DOX cannot be administered patients. Therefore, experiments have directed towards revealing underlying mechanisms responsible resistance ameliorating adverse effects. Nuclear factor erythroid 2-related 2 (Nrf2) signaling activated increase levels reactive oxygen species (ROS) cells protect them against oxidative stress. It reported that Nrf2 activation associated with drug resistance. In exposed DOX, stimulation protects cell death. Various upstream mediators regulate Strategies, both pharmacological genetic interventions, reversing However, induction importance alleviating side effects DOX. Pharmacological agents naturally occurring compounds as the most common amelioration. Furthermore, networks which a key player protection revealed are discussed current review.

Language: Английский

Citations

94
The role of microRNA-338-3p in cancer: growth, invasion, chemoresistance, and mediators DOI
Sepideh Mirzaei, Ali Zarrabi,

Sholeh Etehad Asnaf

et al.

Life Sciences, Journal Year: 2021, Volume and Issue: 268, P. 119005 - 119005

Published: Jan. 7, 2021

Language: Английский

Citations

72
Regulatory role of microRNAs on PTEN signaling DOI Creative Commons
Soudeh Ghafouri‐Fard, Atefe Abak, Hamed Shoorei

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2020, Volume and Issue: 133, P. 110986 - 110986

Published: Nov. 7, 2020

Phosphatase and tensin homolog (PTEN) gene encodes a tumor suppressor protein which is altered in several malignancies. This negative regulator of the PI3K/AKT signaling. Several transcription factors regulate expression PTEN positive or directions. Moreover, numerous microRNAs (miRNAs) have functional interactions with inhibit its expression. Suppression can attenuate response cancer cells to chemotherapeutic agents. Based on critical role this gene, identification regulators has practical significance particularly prevention management cancer. Meanwhile, interaction between miRNAs consequences non-malignant disorders including myocardial infarction, osteoporosis, cerebral ischemic stroke, recurrent abortion. In present review, we describe regulation activity PTEN.

Language: Английский

Citations

71
Small in Size, but Large in Action: microRNAs as Potential Modulators of PTEN in Breast and Lung Cancers DOI Creative Commons

Asal Jalal Abadi,

Ali Zarrabi, Mohammad Gholami

et al.

Biomolecules, Journal Year: 2021, Volume and Issue: 11(2), P. 304 - 304

Published: Feb. 18, 2021

MicroRNAs (miRNAs) are well-known regulators of biological mechanisms with a small size 19-24 nucleotides and single-stranded structure. miRNA dysregulation occurs in cancer progression. miRNAs can function as tumor-suppressing or tumor-promoting factors via regulating molecular pathways. Breast lung cancers two malignant thoracic tumors which the abnormal expression plays significant role their development. Phosphatase tensin homolog (PTEN) is tumor-suppressor factor that capable suppressing growth, viability, metastasis cells downregulating phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling. PTEN downregulation breast to promote PI3K/Akt expression, leading uncontrolled proliferation, metastasis, resistance chemotherapy radiotherapy. upstream mediators dually induce/inhibit signaling affecting behavior cells. Furthermore, long non-coding RNAs circular regulate miRNA/PTEN axis It seems anti-tumor compounds such baicalein, propofol, curcumin induce upregulation by These topics discussed current review focus on

Language: Английский

Citations

62
Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers DOI Creative Commons
Yiyin Zhang, Qijiang Mao,

Qiming Xia

et al.

Journal of Hematology & Oncology, Journal Year: 2021, Volume and Issue: 14(1)

Published: Oct. 15, 2021

Abstract Altered metabolic patterns in tumor cells not only meet their own growth requirements but also shape an immunosuppressive microenvironment through multiple mechanisms. Noncoding RNAs constitute approximately 60% of the transcriptional output human and have been shown to regulate numerous cellular processes under developmental pathological conditions. Given extensive action mechanisms based on motif recognition patterns, noncoding may serve as hinges bridging activity immune responses. Indeed, recent studies that microRNAs, long circRNAs are widely involved rewiring, cell infiltration function. Hence, we summarized existing knowledge role remodeling metabolism microenvironment, notably, established TIMELnc manual, which is a free public manual for researchers identify pivotal lncRNAs simultaneously correlated with bioinformatic approach.

Language: Английский

Citations

62
PD-L1: expression regulation DOI Creative Commons
Yujie Zhou,

Guoli Li,

Jiyin Wang

et al.

Blood Science, Journal Year: 2023, Volume and Issue: 5(2), P. 77 - 91

Published: Jan. 13, 2023

Programmed death-ligand 1 (PD-L1), expressed on the surface of tumor cells, can bind to programmed cell death-1 (PD-1) T cells. The interaction PD-1 and PD-L1 inhibit T-cell responses by decreasing activity accelerating their apoptosis. Various cancers express high levels exploit PD-L1/PD-1 signaling evade immunity, immunotherapies targeting PD-1/PD-L1 axis have been shown exert remarkable anti-tumor effects; however, not all patients benefit from these therapies. Therefore, study mechanisms regulating expression are imperative. In this review, we explore regulation in contexts gene transcription, pathways, histone modification remodeling, microRNAs, long noncoding RNAs, post-translational modification. Current developments studies agents that block correlations between also summarized. Our review will assist understanding discusses implications reported findings cancer diagnosis immunotherapy.

Language: Английский

Citations

30
MicroRNAs as important players in regulating cancer through PTEN/PI3K/AKT signalling pathways DOI
Sushmaa Chandralekha Selvakumar,

K. Auxzilia Preethi,

Durairaj Sekar

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2023, Volume and Issue: 1878(3), P. 188904 - 188904

Published: May 1, 2023

Language: Английский

Citations

26